KWKerui Wu

Kerui Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kerui Wu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Abhishek Tyagi

    Department of Cancer Biology, Wake Forest Baptist Medical Center, Winston-Salem, USA

    3 shared publications
  • Kounosuke Watabe

    Department of Cancer Biology, Wake Forest Baptist Medical Center , Winston-Salem, North Carolina

    3 shared publications
  • Ravindra Pramod Deshpande

    Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, USA

    2 shared publications
  • Shih-Ying Wu

    Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, USA

    2 shared publications
  • Chenghu Wu

    Joint Centre of Translational Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China; Joint Centre of Translational Medicine, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China; Zhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang 325000, China

    1 shared publication
  • Daliya Banerjee

    Nirogy Therapeutics, Framingham, MA

    1 shared publication

Latest Publications

  • Open Access

    Macrophage‐Targeted Magnesium Ion‐Nourisher for NLRP3 Inflammasome Inhibition to Enhance Liver Inflammatory Disease Treatment

    by Li Wang, Zhuo Yan, Sindhu Yalavarthi, Yusif Abdul‐Rashid, Kiki Parker, Kyle Nowlin, Ethan Li, Jordan Mack, Josephine Wei, Hunter Vu, et al.

    Magnesium (Mg) exerts important functions in immune regulation. Fluctuations of Mg levels significantly impact immune cell behavior, such as differentiation and inflammatory phenotypes of macrophages. However, exploiting Mg as an immunomodulatory intervention is challenging due to its unclear mechanism and broad impact across diverse cells. To overcome this, a nanosized Mg ion‐nourisher is engineered, termed MgC @PS , that enables efficient macrophage‐targeted intracellular Mg 2 ⁺ (iMg 2+ ) delivery by exploiting macrophages’ efferocytosis in response to phosphatidylserine. It is found that targeted enrichment of magnesium ions (Mg 2 ⁺) into macrophages effectively inhibits NOD‐like receptor pyrin domain containing 3 (NLRP3) inflammasome activation‐induced pyroptosis, and alleviates hyperactive inflammatory responses. Single‐cell RNA sequencing reveals fortified resilience of Kupffer cells from pyroptosis and upregulation of antioxidant gene expression after MgC @PS treatment. Moreover, by incorporating stem cell components into the MgC @PS , the integrity of the intestinal barrier, addressing the barrier leakage commonly observed in the gut‐liver axis. These findings demonstrate the pivotal role of iMg 2 ⁺ in mitigating macrophage‐mediated liver‐gut inflammation. Targeted delivery of Mg to macrophages emerges as a promising strategy to inhibit excessive inflammation and promote tissue recovery.


  • Open Access

    Ghrelin-induced neuronal NPY promotes brain metastasis in lung cancer patients with low BMI

    by Abhishek Tyagi, Shih-Ying Wu, Jee-Won Kim, Ravindra Pramod Deshpande, Kerui Wu, Eleanor C. Smith, Giuseppe L. Banna, Kounosuke Watabe

    Obesity is a known risk factor for many cancers, yet recent studies reveal a paradoxical association between low body mass index (BMI) and increased brain metastasis in lung cancer—referred to as the “obesity paradox,” with unclear molecular mechanism(s). Here, we show a significantly higher incidence of brain metastasis in low-BMI lung cancer patients compared to those with high-BMI or other cancer brain metastasis in a pan-analysis of 7628 patients. Mechanistically, low BMI activates ghrelin-GHSR signaling, increasing neuronal neuropeptide Y (NPY) secretion, which promotes tumor metabolic reprogramming via NPY-Y5R, facilitating brain colonization. Elevated plasma ghrelin levels in cancer-free low-BMI subjects suggest its potential as a prognostic biomarker for predicting brain metastasis. Notably, targeting NPY-Y5R or reversing low BMI effectively suppresses brain metastasis, supporting its pro-metastatic role. These findings provide a strong rationale for developing targeted interventions to treat or prevent brain metastasis in lung cancer patients with low BMI.


  • Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy

    by Jilong Wang, Chenghu Wu, Yiran Wang, Yecheng Shen, Kerui Wu, Yikai Shi, Tianshou Cao, Shanshan Yuan, Yuting Zhu, Yongheng Bai, et al.


  • Open Access

    Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence

    by Kerui Wu, Feng Lyu, Shih-Ying Wu, Sambad Sharma, Ravindra Pramod Deshpande, Abhishek Tyagi, Dan Zhao, Fei Xing, Ravi Singh, Kounosuke Watabe

    Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved by anchoring membrane-bound bioactive interleukin 2 (IL2) and enriching T cell–promoting costimulatory factors on the surface of the dendritic cell–derived small extracellular vesicles. This nanovesicle also displays major histocompatibility complex–bound antigens inherited from tumor lysate–pulsed dendritic cell. When administrated, the surface-bound IL2 is able to guide the nanovesicle to lymphoid organs and activate the IL2 receptor on lymphocytes. Furthermore, it is able to perform antigen presentation in the replacement of professional antigen-presenting cells. This nanovesicle, named IL2-ep13nsEV, induced a strong immune reaction to rescue 50% of the mice in our humanized patient-derived xenografts, sensitized cancer cells to immune checkpoint inhibitor treatment, and prevented the recurrence of resected tumors. This paradigm presents a feasible strategy for the treatment and prevention of metastatic breast cancer.


  • Open Access

    Abstract 2652: Efficacy of a small molecule MCT1 and MCT4 transporter inhibitor in cancer

    by Sambad Sharma, Gregory Goreczny, Nicole Bowman, Jennifer Duffy, Daliya Banerjee, Sanath Wijerathna, John Dzuris, Kerui Wu, Shih-Ying Wu, Abhishek Tyagi, et al.

    Targeting metabolic pathways has been a major clinical interest to effectively treat cancer patients. FDA approval of TIVSOVO(R) (IDH1 inhibitor) has validated the clinical importance of targeting tumor metabolism in cancer. Although MCT1-targeting small molecule inhibitor is currently under investigation for lymphoid cancers, the therapeutic efficacy of this compound is compromised by compensatory overexpression of MCT4 by tumor cells. Therefore, there is a need for a dual MCT1/4 inhibitor to target cancer. We have developed a first-in-class orally bioavailable small molecule inhibitor that targets lactate transport through MCT1 and MCT4 transporters. In 4T1 syngeneic model, we observed a significant dose-dependent reduction of tumor growth by NGY-B treatment that also correlated with serum lactate levels. Immunoprofiling of tumors revealed that NGY-B promoted anti-tumor immune response in 4T1 tumor bearing mice indicating simultaneous immune activation. Also, the combination of NGY-B with a checkpoint inhibitor led to greater efficacy and overall survival in this model suggesting a potential combination therapy in the clinic. Furthermore, we demonstrated the direct tumor cell killing effect of NGY-B in multiple human CDX and PDX models. Therefore, NGY-B intervenes two key hallmarks of cancer - tumor metabolism and anti-tumor immunity, and provides a novel modality to therapeutically target cancer. Citation Format: Sambad Sharma, Gregory Goreczny, Nicole Bowman, Jennifer Duffy, Daliya Banerjee, Sanath Wijerathna, John Dzuris, Kerui Wu, Shih-Ying Wu, Abhishek Tyagi, Kounosuke Watabe, Jaime Escobedo, Vincent Sandanayaka. Efficacy of a small molecule MCT1 and MCT4 transporter inhibitor in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2652.